Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan.

LeVine H 3rd, Spielmann HP, Matveev S, Cauvi FM, Murphy MP, Beckett TL, McCarty K, Lott IT, Doran E, Schmitt F, Head E.

Neurobiol Aging. 2017 Jun;54:163-169. doi: 10.1016/j.neurobiolaging.2017.03.005. Epub 2017 Mar 14.

2.

Structure and specificity of a permissive bacterial C-prenyltransferase.

Elshahawi SI, Cao H, Shaaban KA, Ponomareva LV, Subramanian T, Farman ML, Spielmann HP, Phillips GN Jr, Thorson JS, Singh S.

Nat Chem Biol. 2017 Apr;13(4):366-368. doi: 10.1038/nchembio.2285. Epub 2017 Feb 6.

3.

Formation of a Novel Macrocyclic Alkaloid from the Unnatural Farnesyl Diphosphate Analogue Anilinogeranyl Diphosphate by 5-Epi-Aristolochene Synthase.

Rising KA, Crenshaw CM, Koo HJ, Subramanian T, Chehade KA, Starks C, Allen KD, Andres DA, Spielmann HP, Noel JP, Chappell J.

ACS Chem Biol. 2015 Jul 17;10(7):1729-36. doi: 10.1021/acschembio.5b00145. Epub 2015 May 4.

4.

Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors.

Holland AJ, Reis RM, Niessen S, Pereira C, Andres DA, Spielmann HP, Cleveland DW, Desai A, Gassmann R.

Mol Biol Cell. 2015 May 15;26(10):1845-56. doi: 10.1091/mbc.E14-11-1560. Epub 2015 Mar 25.

5.

Novel Citronellyl-Based Photoprobes Designed to Identify ER Proteins Interacting with Dolichyl Phosphate in Yeast and Mammalian Cells.

Rush JS, Subramanian T, Subramanian KL, Onono FO, Waechter CJ, Spielmann HP.

Curr Chem Biol. 2015;9(2):123-141.

6.

Design and synthesis of non-hydrolyzable homoisoprenoid α-monofluorophosphonate inhibitors of PPAPDC family integral membrane lipid phosphatases.

Subramanian T, Ren H, Subramanian KL, Sunkara M, Onono FO, Morris AJ, Spielmann HP.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4414-4417. doi: 10.1016/j.bmcl.2014.08.013. Epub 2014 Aug 12.

7.

A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain.

Matveev SV, Spielmann HP, Metts BM, Chen J, Onono F, Zhu H, Scheff SW, Walker LC, LeVine H 3rd.

J Neurochem. 2014 Nov;131(3):356-68. doi: 10.1111/jnc.12815. Epub 2014 Jul 28.

8.

Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion.

Chen M, Knifley T, Subramanian T, Spielmann HP, O'Connor KL.

PLoS One. 2014 Feb 26;9(2):e89892. doi: 10.1371/journal.pone.0089892. eCollection 2014.

9.

Syntheses of deuterium labeled prenyldiphosphate and prenylcysteine analogues for in vivo mass spectrometric quantification.

Subramanian T, Subramanian KL, Sunkara M, Onono FO, Morris AJ, Spielmann HP.

J Labelled Comp Radiopharm. 2013 Jun 30;56(8):370-5. doi: 10.1002/jlcr.3049. Epub 2013 May 9.

PMID:
24285475
10.

Identification of a farnesol analog as a Ras function inhibitor using both an in vivo Ras activation sensor and a phenotypic screening approach.

Srinivasan K, Subramanian T, Spielmann HP, Janetopoulos C.

Mol Cell Biochem. 2014 Feb;387(1-2):177-86. doi: 10.1007/s11010-013-1883-4. Epub 2013 Nov 6.

11.

Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathway.

Onono F, Subramanian T, Sunkara M, Subramanian KL, Spielmann HP, Morris AJ.

J Biol Chem. 2013 Sep 20;288(38):27444-55. doi: 10.1074/jbc.M113.482307. Epub 2013 Aug 1.

12.

Synthesis of Farnesol Analogues Containing Triazoles in Place of Isoprenes through 'Click Chemistry'

Subramanian T, Parkin S, Spielmann HP.

Synlett. 2012 Oct;23(17):2539-2543.

13.

Farnesyl diphosphate analogues with aryl moieties are efficient alternate substrates for protein farnesyltransferase.

Subramanian T, Pais JE, Liu S, Troutman JM, Suzuki Y, Leela Subramanian K, Fierke CA, Andres DA, Spielmann HP.

Biochemistry. 2012 Oct 16;51(41):8307-19. doi: 10.1021/bi3011362. Epub 2012 Oct 2.

14.

Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24.

Chang SY, Hudon-Miller SE, Yang SH, Jung HJ, Lee JM, Farber E, Subramanian T, Andres DA, Spielmann HP, Hrycyna CA, Young SG, Fong LG.

J Lipid Res. 2012 Jun;53(6):1176-82. doi: 10.1194/jlr.M026161. Epub 2012 Mar 23.

15.

Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.

Morgan MA, Onono FO, Spielmann HP, Subramanian T, Scherr M, Venturini L, Dallmann I, Ganser A, Reuter CW.

J Mol Med (Berl). 2012 Feb;90(2):149-61. doi: 10.1007/s00109-011-0814-7. Epub 2011 Sep 14.

PMID:
21915711
16.

Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.

Yang SH, Chang SY, Ren S, Wang Y, Andres DA, Spielmann HP, Fong LG, Young SG.

Hum Mol Genet. 2011 Feb 1;20(3):436-44. doi: 10.1093/hmg/ddq490. Epub 2010 Nov 18.

17.

Anticancer activity of novel unnatural synthetic isoprenoids.

Adams VR, Deremer DL, Stevich B, Mattingly CA, Gallt B, Subramanian T, Troutman JM, Spielmann HP.

Anticancer Res. 2010 Jul;30(7):2505-12.

PMID:
20682975
18.

Development, in vitro testing, and clinical use of a 3.5 mm-diameter zirconia abutment.

Grunder U, Spielmann HP, Snétivy D.

Eur J Esthet Dent. 2010 Summer;5(2):158-70.

PMID:
20589260
19.

An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.

Davies BS, Barnes RH 2nd, Tu Y, Ren S, Andres DA, Spielmann HP, Lammerding J, Wang Y, Young SG, Fong LG.

Hum Mol Genet. 2010 Jul 1;19(13):2682-94. doi: 10.1093/hmg/ddq158. Epub 2010 Apr 26.

20.

Functional characterization of the atypical integral membrane lipid phosphatase PDP1/PPAPDC2 identifies a pathway for interconversion of isoprenols and isoprenoid phosphates in mammalian cells.

Miriyala S, Subramanian T, Panchatcharam M, Ren H, McDermott MI, Sunkara M, Drennan T, Smyth SS, Spielmann HP, Morris AJ.

J Biol Chem. 2010 Apr 30;285(18):13918-29. doi: 10.1074/jbc.M109.083931. Epub 2010 Jan 28.

21.

A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting.

Onono FO, Morgan MA, Spielmann HP, Andres DA, Subramanian T, Ganser A, Reuter CW.

Mol Cell Proteomics. 2010 Apr;9(4):742-51. doi: 10.1074/mcp.M900597-MCP200. Epub 2010 Jan 26.

22.

Cdc20 is required for the post-anaphase, KEN-dependent degradation of centromere protein F.

Gurden MD, Holland AJ, van Zon W, Tighe A, Vergnolle MA, Andres DA, Spielmann HP, Malumbres M, Wolthuis RM, Cleveland DW, Taylor SS.

J Cell Sci. 2010 Feb 1;123(Pt 3):321-30. doi: 10.1242/jcs.062075. Epub 2010 Jan 5.

23.

Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.

Yang SH, Chang SY, Andres DA, Spielmann HP, Young SG, Fong LG.

J Lipid Res. 2010 Feb;51(2):400-5. doi: 10.1194/jlr.M002808. Epub 2009 Oct 26.

24.

Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides.

Fong LG, Vickers TA, Farber EA, Choi C, Yun UJ, Hu Y, Yang SH, Coffinier C, Lee R, Yin L, Davies BS, Andres DA, Spielmann HP, Bennett CF, Young SG.

Hum Mol Genet. 2009 Jul 1;18(13):2462-71. doi: 10.1093/hmg/ddp184. Epub 2009 Apr 17.

25.

Protein farnesyltransferase-catalyzed isoprenoid transfer to peptide depends on lipid size and shape, not hydrophobicity.

Subramanian T, Liu S, Troutman JM, Andres DA, Spielmann HP.

Chembiochem. 2008 Nov 24;9(17):2872-82. doi: 10.1002/cbic.200800248.

26.

Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated.

Yang SH, Andres DA, Spielmann HP, Young SG, Fong LG.

J Clin Invest. 2008 Oct;118(10):3291-300. doi: 10.1172/JCI35876.

27.

Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome.

Davies BS, Yang SH, Farber E, Lee R, Buck SB, Andres DA, Spielmann HP, Agnew BJ, Tamanoi F, Fong LG, Young SG.

J Lipid Res. 2009 Jan;50(1):126-34. doi: 10.1194/jlr.M800424-JLR200. Epub 2008 Aug 29.

28.

A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.

Coffinier C, Hudon SE, Lee R, Farber EA, Nobumori C, Miner JH, Andres DA, Spielmann HP, Hrycyna CA, Fong LG, Young SG.

J Biol Chem. 2008 Apr 11;283(15):9797-804. doi: 10.1074/jbc.M709629200. Epub 2008 Jan 28.

29.

Protein farnesyl transferase target selectivity is dependent upon peptide stimulated product release.

Troutman JM, Andres DA, Spielmann HP.

Biochemistry. 2007 Oct 9;46(40):11299-309. Epub 2007 Sep 18.

PMID:
17877368
31.

Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging.

Dechat T, Shimi T, Adam SA, Rusinol AE, Andres DA, Spielmann HP, Sinensky MS, Goldman RD.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4955-60. Epub 2007 Mar 14.

32.

Hydrophilic anilinogeranyl diphosphate prenyl analogues are Ras function inhibitors.

Roberts MJ, Troutman JM, Chehade KA, Cha HC, Kao JP, Huang X, Zhan CG, Peterson YK, Subramanian T, Kamalakkannan S, Andres DA, Spielmann HP.

Biochemistry. 2006 Dec 26;45(51):15862-72. Epub 2006 Dec 6.

PMID:
17176109
34.

Tools to analyze protein farnesylation in cells.

Troutman JM, Roberts MJ, Andres DA, Spielmann HP.

Bioconjug Chem. 2005 Sep-Oct;16(5):1209-17.

PMID:
16173800
35.

Directed library of anilinogeranyl analogues of farnesyl diphosphate via mixed solid- and solution-phase synthesis.

Subramanian T, Wang Z, Troutman JM, Andres DA, Spielmann HP.

Org Lett. 2005 May 26;7(11):2109-12.

PMID:
15901146
36.

Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate.

Troutman JM, Chehade KA, Kiegiel K, Andres DA, Spielmann HP.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4979-82.

PMID:
15341963
37.

A model for initial DNA lesion recognition by NER and MMR based on local conformational flexibility.

Isaacs RJ, Spielmann HP.

DNA Repair (Amst). 2004 May 4;3(5):455-64. Review.

PMID:
15162792
38.
39.

Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity.

Minutolo F, Bertini S, Betti L, Di Bussolo V, Giannaccini G, Placanica G, Rapposelli S, Spielmann HP, Macchia M.

Farmaco. 2003 Dec;58(12):1277-81.

PMID:
14630239
40.
41.

Alkylation of dihydrofullerenes.

Meier MS, Bergosh RG, Gallagher ME, Spielmann HP, Wang Z.

J Org Chem. 2002 Aug 23;67(17):5946-52.

PMID:
12182626
42.

Photoaffinity analogues of farnesyl pyrophosphate transferable by protein farnesyl transferase.

Chehade KA, Kiegiel K, Isaacs RJ, Pickett JS, Bowers KE, Fierke CA, Andres DA, Spielmann HP.

J Am Chem Soc. 2002 Jul 17;124(28):8206-19.

PMID:
12105898
43.

A (13)C INADEQUATE and HF-GIAO study of C(60)H(2) and C(60)H(6) identification of ring currents in a 1,2-dihydrofullerene.

Meier MS, Spielmann HP, Bergosh RG, Haddon RC.

J Am Chem Soc. 2002 Jul 10;124(27):8090-4.

PMID:
12095353
45.

Computer-assisted generation of all-ceramic crowns and fixed partial dentures.

Besimo CE, Spielmann HP, Rohner HP.

Int J Comput Dent. 2001 Oct;4(4):243-62. English, German.

PMID:
11939100
46.

Protein farnesyltransferase isoprenoid substrate discrimination is dependent on isoprene double bonds and branched methyl groups.

Micali E, Chehade KA, Isaacs RJ, Andres DA, Spielmann HP.

Biochemistry. 2001 Oct 16;40(41):12254-65.

PMID:
11591144
47.
48.

Preparation, NMR characterization, and labeling reactions of tritiated triacetoxy sodium borohydride.

Than C, Morimoto H, Williams PG, Chehade KA, Andres DA, Spielmann HP.

J Org Chem. 2001 May 18;66(10):3602-5. No abstract available.

PMID:
11348153
50.

Facile and efficient synthesis of 4-azidotetrafluoroaniline: a new photoaffinity reagent.

Chehade KA, Spielmann HP.

J Org Chem. 2000 Aug 11;65(16):4949-53.

PMID:
10956477

Supplemental Content

Loading ...
Support Center